High Tech Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
High Tech Pharm makes active pharmaceutical ingredients, the purified chemical compounds that drug manufacturers use to produce finished injectable antibiotics.
It specialises in carbapenem-class antibiotics, a group of broad-spectrum antibiotics used in hospitals to treat serious bacterial infections, with its main products being imipenem and ertapenem. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company supplies almost entirely to overseas pharmaceutical manufacturers, with Europe accounting for the large majority of its revenue.
Summary is AI-generated and may contain errors · figures from DART filings
The company applies a proprietary crystallisation process it says achieves higher yields and lower impurity levels than competing methods, which it treats as a core production differentiator.
High Tech Pharm in five facts
What does High Tech Pharm do?
High Tech Pharm makes active pharmaceutical ingredients, the purified chemical compounds that drug manufacturers use to produce finished injectable antibiotics.
Where is High Tech Pharm listed and in which sector?
High Tech Pharm (Korean name: 하이텍팜) trades under KRX code 106190 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is High Tech Pharm?
Its market capitalisation was US$75.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were High Tech Pharm's latest annual revenue and operating profit?
For fiscal year 2025, High Tech Pharm reported revenue of US$53M, operating profit of US$9.7M and net income of US$8.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 9.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.